Pharmaceuticals giant Pfizer has said that it’s concluded the Phase 3 trial of its Covid-19 vaccine candidate and recorded a 95% efficacy rate compared to the 90% that it previously reported last week when it hadn’t concluded its trials. 

Pfizer says it conducted its trials on over 43,000 participants wherein two equal groups were administered with its vaccine candidate and a placebo drug. The company says it recorded 170 confirmed cases of Covid-19 28 days after it administered the first vaccine dose, of which just 2 came up from the group given its vaccine while 168 came from the group administered the placebo.

Pfizer’s announcement comes just on the heels of another biotech company, Moderna, having announced the trial results of its own Covid-19 vaccine candidate and reporting a 94.5% efficacy rate. 

Pfizer came up with its Covid-19 vaccine candidate in partnership with BioNTech, a publicly-traded German biotechnology company. With the Phase 3 trials concluded, the company says it’ll request for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and also seek approval from other global health regulatory agencies.

In its trials, Pfizer notes that 10 severe cases of Covid-19 were observed, nine from the placebo group and one from the vaccinated group.

Photo: Pfizer CEO Albert Bourla by World Economic Forum is licensed under CC BY-NC-SA 2.0

Share this...

Facebook

Pinterest

Twitter

Linkedin

Whatsapp

Email

Print